Dynavax Technologiesoration (DVAX) 4.04 -0.10

Dynavax Technologies Corporation
(DVAX) 4.04 -0.10

Last Trade:	4.05	Day Range:	3.94 - 4.19
Trade Time:	08:02PM	52wk Range:	1.75 - 4.48
Prev. Close:	4.15	Market Cap:	513.58M
Open:	4.15	Div Yield:	0
Volume:	1816938	PE:
EPS:	-0.49

The Latest On DVAX

Weekly Traders Homework: The First Sign Of Weakness In 2012 (w/ Economic Calendar & Stock Radar) 2/12/12 10:52pm

Dynavax Reports on Heplisav(TM) Pre-BLA Meeting With FDA 2/2/12 9:01am

JPMorgan Confab Kicks Off Biotech 2012 1/5/12 11:46am

Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist for Asthma 12/21/11 9:00am

Dynavax Initiates Proof of Mechanism Trial in Lupus Patients 12/20/11 9:06am

Dynavax Announces Exercise in Full of Overallotment Option and Completion of Public Offering of Common Stock 11/8/11 4:00pm

Dynavax Prices Public Offering of 24M Shares at $2.50 11/3/11 7:22am

Dynavax Announces Proposed Public Offering of Common Stock; No Amount Given 11/2/11 3:00pm

Dynavax Confirms HEPLISAV Submission Strategies With U.S. FDA and EMA 10/27/11 3:10pm

Dynavax Phase 3 Data in Chronic Kidney Disease Demonstrates Superiority of HEPLISAV vs Engerix-B 10/27/11 6:11am

Notable Call Options Activity in Dynavax Technologies 10/26/11 10:19am

Dynavax and GlaxoSmithKline Expand Their Worldwide Strategic Alliance 10/21/11 8:02am

Weekly Traders Homework: The First Sign Of Weakness In 2012 (w/ Economic Calendar & Stock Radar) 2/12/12

Dynavax Reports on Heplisav(TM) Pre-BLA Meeting With FDA 2/2/12

JPMorgan Confab Kicks Off Biotech 2012 1/5/12

Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist for Asthma 12/21/11

Dynavax Initiates Proof of Mechanism Trial in Lupus Patients 12/20/11

Dynavax Announces Exercise in Full of Overallotment Option and Completion of Public Offering of Common Stock 11/8/11

Dynavax Prices Public Offering of 24M Shares at $2.50 11/3/11

Dynavax Announces Proposed Public Offering of Common Stock; No Amount Given 11/2/11

Dynavax Confirms HEPLISAV Submission Strategies With U.S. FDA and EMA 10/27/11

Dynavax Phase 3 Data in Chronic Kidney Disease Demonstrates Superiority of HEPLISAV vs Engerix-B 10/27/11

Notable Call Options Activity in Dynavax Technologies 10/26/11

Dynavax and GlaxoSmithKline Expand Their Worldwide Strategic Alliance 10/21/11

Weekly Traders Homework: The First Sign Of Weakness In 2012 (w/ Economic Calendar & Stock Radar) 2/12/12

NASDAQ's Top Gainers for Monday: PAETEC, Sify Technologies, Dynavax, Limelight Networks 8/2/11

NASDAQ Top Percentage Gainers: Town Sports International, AXT, Dynavax, Green Mountain Coffee Roasters 7/29/11

Top Percentage Gainers and Losers as of 12pm 6/23/11 6/23/11

Benzinga’s Top Upgrades (MS, TDC, HAL, DVAX, SUPX) 5/13/10

Market Round-up (GNW, NLX-U, DVAX, BKS, BGP) 1/26/10

Jefferies Reports Favorable ACIP Stance For Dynavax Tech 6/24/11

Jefferies Maintains Buy on Dynavax Technologies 6/9/11

Wedbush Initiates Coverage On Dynavax With Outperform Rating 3/25/11

Jefferies & Company Initiates Coverage on Dynavax Technologies 11/8/10

Jefferies Initiates Buy Rating on Dynavax Technologies 11/8/10

Oppenheimer's Current Biotech Ratings 9/13/10

Dynavax (DVAX) Upgraded To Outperform 5/13/10

Benzinga’s Top Upgrades (MS, TDC, HAL, DVAX, SUPX) 5/13/10

Trade DVAX
NOW!

Partner Headlines

8 Stocks Under $10 Moving Higher 2/2/12

10 Stocks of Top-Performing Funds in 2012 1/20/12

Dynavax Technologies Corp. Reports Operating Results (10-Q) 10/31/11

Biotech Calendar: Key Dates for October 10/2/11

Biotech Calendar: Key Dates for September 8/31/11

Dynavax, Frontier Financial: Early Volume Plays 4/27/10

Dynavax, Santarus: Early Volume Plays 4/15/10

Sirius XM, Conolog: Early Volume Plays 3/23/10

Press Releases

Get the latest DVAX stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Dynavax Technologies Corporation stock price.

Dynavax Technologies Corporation by YCharts